Prospective comparison of a bovine collagen dressing to bovine spray thrombin for control of haemorrhage of skin graft donor sites

Prasad, J.K.; Taddonio, T.E.; Thomson, Philip D.

doi:10.1016/0305-4179(91)90018-c

Cited by 7 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of previous trials have evaluated a range of agents, including fibrin sealants, thrombin, adrenaline, and collagen. [1][2][3][4][5][6][7][8] Although the severity of bleeding is diffuse and not often severe, the wounds provide a good model for the evaluation of new surgical hemostatic materials. Skin graft donor sites are prepared in a reproducible and controlled manner, and the wounds provide a good model for the evaluation of new surgical hemostatic materials.…”

mentioning

confidence: 99%

Hemostatic Effect of Vivostat Patient-Derived Fibrin Sealant on Split-Thickness Skin Graft Donor Sites

Drake¹,

Wong²

2003

Annals of Plastic Surgery

View full text Add to dashboard Cite

Topical hemostatic agents are used frequently to control bleeding of skin graft donor sites. In this study, the hemostatic properties of Vivostat (Vivolution A/S, Birkerød, Denmark) patient-derived fibrin sealant were compared with a control group of spray thrombin solution, which is considered an industry standard for topical hemostasis. Treatments were applied simultaneously to two randomly chosen halves of a single split-thickness single donor site in patients in five United States surgical centers. The time to achieve satisfactory hemostasis (< or =10 min) was estimated on each half of the wound as the time at which active bleeding had stopped and the wound was suitable for application of a surgical dressing. The time to hemostasis of wounds treated with Vivostat (Vivolution A/S) patient-derived sealant was significantly shorter in comparison with wounds treated with thrombin solution (medians: Vivostat, 31 seconds; thrombin, 58 seconds; p=0.0012). No abnormalities in wound healing were reported for either treatment site 1 week after the operation. Vivostat (Vivolution A/S) sealant is a more rapidly effective topical hemostatic agent than thrombin on split-thickness skin graft donor sites.

show abstract

mentioning

confidence: 99%

Hemostatic Effect of Vivostat Patient-Derived Fibrin Sealant on Split-Thickness Skin Graft Donor Sites

Drake¹,

Wong²

2003

Annals of Plastic Surgery

View full text Add to dashboard Cite

show abstract

“…There was also interest in the use of thrombin for the treatment of burns (141) but it would appear that the use of epinephrine has supplanted thrombin in the treatment of bleeding secondary to burns (142)(143)(144)(145)(146)(147). There are also uses in other areas of surgery (148)(149)(150)(151)(152)(153)(154)(155)(156)(157)(158).…”

Section: Therapeutic Uses Of Thrombinmentioning

confidence: 99%

A review of the therapeutic uses of thrombin

Lundblad

Bradshaw

Gabriel³

et al. 2004

Thromb Haemost

View full text Add to dashboard Cite

Thrombin is the product of the hemostatic response essential to the conversion of fibrinogen to fibrin. In addition, it is also responsible for the aggregation of blood platelets in the formation of the "platelet plug" as well as the activation of factor VIII, factor V, factor XI, factor XIII and protein C. The action of thrombin is not confined to the hemostatic response as it also has a critical function in the wound healing process by stimulating 'mitogenic' events through interaction with cell surface receptors. In this review, we consider the various biological activities of thrombin as they relate to current therapeutic use. While there has been considerable interest in the development of fibrin sealant products, there has been considerably less interest in documenting the continuing use of thrombin as a therapeutic. The use of thrombin for topical hemostasis and the treatment of pseudoaneurysms will be discussed in detail. It is concluded that the use of thrombin as a drug will not only continue but also will significantly increase. However, the availability of a safe human thrombin preparation will be critical for the continued use of thrombin as a therapeutic.

show abstract